A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Phase 2
144
about 1.9 years
18+
9 sites in AZ, CA, FL +2
What this study is about
This trial is testing a treatment called SAR445399 for hidradenitis suppurativa. This is a Phase 2 trial, meaning it's evaluating different doses of the drug to see if it works and is safe in adults with moderate to severe hidradenitis suppurativa.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Placebo
- 2.Take SAR445399
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Secondary: Absolute change from baseline to Week 16 in International Hidradenitis Suppurativa Severity Score System (IHS4), Absolute change from baseline to Week 16 in draining tunnel count, Absolute change from baseline to Week 16 in the Dermatology Life Quality Index (DLQI) score, Absolute change from baseline to Week 16 in the total Hidradenitis Suppurativa Quality of Life (HiSQoL) score, Change from baseline to Week 16 in Weekly average HS-SAQ score items, Change from baseline to Week 16 in the Hidradenitis Suppurativa Impact Assessment Questionnaire (HS-IAQ) score, Improvement in Peak Pruritus Numerical Rating Scale (PP-NRS) at Week 16, Number of participants with Treatment Emergent Adverse Events (TEAEs) Adverse Events of Special Interest (AESIs), and Serious Adverse Events (SAEs) including administration site reactions